SOPHiA GENETICS SA

SOPH · NASDAQ

$6.93+$0.44 (+6.78%)TodayMarket closed · Oct 20, 7:31 PM ET

Prev close $6.49

SOPH analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $9.94 (+43.5% upside)

Low: $7.07
Now: $6.93
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

SOPH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 12, 2026	Maintains	Buy	$14.00	43%
HC Wainwright & Co.	Aug 5, 2026	Maintains	Buy	$12.00 → $14.00	43%
BTIG	Aug 5, 2026	Maintains	Buy	$8.00 → $9.00	54%
HC Wainwright & Co.	Jul 20, 2026	Initiates	Buy	$12.00	43%
BTIG	Jun 15, 2026	Maintains	Buy	$8.00	54%
BTIG	May 6, 2026	Maintains	Buy	$8.00	54%
BTIG	Apr 15, 2026	Maintains	Buy	$7.00 → $8.00	54%
Guggenheim	Jan 26, 2026	Maintains	Buy	$6.00 → $7.00	66%
BTIG	Nov 10, 2025	Maintains	Buy	$6.00 → $7.00	54%

The case for and against

Updated Oct 16, 2026

Bull case

Sophia Genetics is well positioned because its cloud-based, pay-per-analysis SaaS model turns genomic interpretation into recurring revenue while insulating the company from lab ownership and reimbursement risk, and its adjusted gross margin reached 74.2% in 2025 and 75.4% in 1Q26. Its moat is reinforced by a compounding data network used by roughly 1,000 institutions across 75 countries, with more than 2.5M genomic profiles analyzed and nearly 33K new profiles added monthly at year-end 2025, which should keep improving algorithms and retention. Growth catalysts include a record 2025 order book, 2026 revenue guidance of $92M–$94M, net dollar retention of 117% in 1Q26, and deepening U.S. and biopharma partnerships with MSK, MD Anderson, and AstraZeneca that expand volume and broaden monetization.

Bear case

Sophia Genetics is facing a weak fundamental setup because its 2024 performance showed only 4% revenue growth despite 11% volume growth, implying a 6-7% decline in revenue per analysis and signaling pricing or mix pressure, especially from biopharma customers. The bearish view also assumes BioPharma DDM remains only about 5% of revenue from 2026 to 2033, with peak revenue limited to $441M and gross margins stuck near 70%, which suggests muted operating leverage and limited upside from its platform. Profitability remains a major concern, as FY2025 net loss was $79.0M and the business still depends on commercial expansion, while competition, cybersecurity, legal/IP disputes, and potential dilution further threaten shareholder returns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.